These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Alternative Virus-Like Particle-Associated Prefusion F Proteins as Maternal Vaccines for Respiratory Syncytial Virus. Blanco JCG; Fernando LR; Zhang W; Kamali A; Boukhvalova MS; McGinnes-Cullen L; Morrison TG J Virol; 2019 Dec; 93(23):. PubMed ID: 31511382 [TBL] [Abstract][Full Text] [Related]
5. Assembly and immunological properties of Newcastle disease virus-like particles containing the respiratory syncytial virus F and G proteins. McGinnes LW; Gravel KA; Finberg RW; Kurt-Jones EA; Massare MJ; Smith G; Schmidt MR; Morrison TG J Virol; 2011 Jan; 85(1):366-77. PubMed ID: 20980510 [TBL] [Abstract][Full Text] [Related]
6. Cotton rat immune responses to virus-like particles containing the pre-fusion form of respiratory syncytial virus fusion protein. Cullen LM; Blanco JC; Morrison TG J Transl Med; 2015 Nov; 13():350. PubMed ID: 26541285 [TBL] [Abstract][Full Text] [Related]
7. Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB/c mice, with no evidence of immunopathology. Murawski MR; McGinnes LW; Finberg RW; Kurt-Jones EA; Massare MJ; Smith G; Heaton PM; Fraire AE; Morrison TG J Virol; 2010 Jan; 84(2):1110-23. PubMed ID: 19889768 [TBL] [Abstract][Full Text] [Related]
8. A single intranasal administration of virus-like particle vaccine induces an efficient protection for mice against human respiratory syncytial virus. Jiao YY; Fu YH; Yan YF; Hua Y; Ma Y; Zhang XJ; Song JD; Peng XL; Huang J; Hong T; He JS Antiviral Res; 2017 Aug; 144():57-69. PubMed ID: 28529001 [TBL] [Abstract][Full Text] [Related]
9. Chimeric virus-like particles containing a conserved region of the G protein in combination with a single peptide of the M2 protein confer protection against respiratory syncytial virus infection. Qiao L; Zhang Y; Chai F; Tan Y; Huo C; Pan Z Antiviral Res; 2016 Jul; 131():131-40. PubMed ID: 27154395 [TBL] [Abstract][Full Text] [Related]
10. Virus-Like Particle Vaccine Containing the F Protein of Respiratory Syncytial Virus Confers Protection without Pulmonary Disease by Modulating Specific Subsets of Dendritic Cells and Effector T Cells. Kim KH; Lee YT; Hwang HS; Kwon YM; Kim MC; Ko EJ; Lee JS; Lee Y; Kang SM J Virol; 2015 Nov; 89(22):11692-705. PubMed ID: 26355098 [TBL] [Abstract][Full Text] [Related]
11. Virus-like particle vaccines containing F or F and G proteins confer protection against respiratory syncytial virus without pulmonary inflammation in cotton rats. Hwang HS; Kim KH; Lee Y; Lee YT; Ko EJ; Park S; Lee JS; Lee BC; Kwon YM; Moore ML; Kang SM Hum Vaccin Immunother; 2017 May; 13(5):1031-1039. PubMed ID: 28129031 [TBL] [Abstract][Full Text] [Related]
12. Effect of Previous Respiratory Syncytial Virus Infection on Murine Immune Responses to F and G Protein-Containing Virus-Like Particles. McGinnes Cullen L; Schmidt MR; Morrison TG J Virol; 2019 May; 93(9):. PubMed ID: 30760576 [TBL] [Abstract][Full Text] [Related]
13. The importance of RSV F protein conformation in VLPs in stimulation of neutralizing antibody titers in mice previously infected with RSV. Cullen LM; Schmidt MR; Morrison TG Hum Vaccin Immunother; 2017 Dec; 13(12):2814-2823. PubMed ID: 28604155 [TBL] [Abstract][Full Text] [Related]
14. Additive protection induced by mixed virus-like particles presenting respiratory syncytial virus fusion or attachment glycoproteins. Lee S; Quan FS; Kwon Y; Sakamoto K; Kang SM; Compans RW; Moore ML Antiviral Res; 2014 Nov; 111():129-35. PubMed ID: 25239522 [TBL] [Abstract][Full Text] [Related]
15. A Parainfluenza Virus Vector Expressing the Respiratory Syncytial Virus (RSV) Prefusion F Protein Is More Effective than RSV for Boosting a Primary Immunization with RSV. Liang B; Matsuoka Y; Le Nouën C; Liu X; Herbert R; Swerczek J; Santos C; Paneru M; Collins PL; Buchholz UJ; Munir S J Virol; 2020 Dec; 95(2):. PubMed ID: 33115876 [TBL] [Abstract][Full Text] [Related]
16. Novel Respiratory Syncytial Virus-Like Particle Vaccine Composed of the Postfusion and Prefusion Conformations of the F Glycoprotein. Cimica V; Boigard H; Bhatia B; Fallon JT; Alimova A; Gottlieb P; Galarza JM Clin Vaccine Immunol; 2016 Jun; 23(6):451-9. PubMed ID: 27030590 [TBL] [Abstract][Full Text] [Related]
18. Intranasal Vaccination with a Respiratory-Syncytial-Virus-Based Virus-like Particle Displaying the G Protein Conserved Region Induces Severe Weight Loss and Pathology upon Challenge with Wildtype Respiratory Syncytial Virus. Terhüja M; Siddappa M; Lamichhane P; Meshram CD; Snider TA; Ritchey JW; Oomens AGP Viruses; 2024 May; 16(6):. PubMed ID: 38932136 [TBL] [Abstract][Full Text] [Related]
19. VLPs generated by the fusion of RSV-F or hMPV-F glycoprotein to HIV-Gag show improved immunogenicity and neutralizing response in mice. Trinité B; Durr E; Pons-Grífols A; O'Donnell G; Aguilar-Gurrieri C; Rodriguez S; Urrea V; Tarrés F; Mane J; Ortiz R; Rovirosa C; Carrillo J; Clotet B; Zhang L; Blanco J Vaccine; 2024 May; 42(15):3474-3485. PubMed ID: 38641492 [TBL] [Abstract][Full Text] [Related]
20. Antigenicity and immunogenicity of unique prefusion-mimic F proteins presented on enveloped virus-like particles. Kwon YM; Lee Y; Kim KH; Jung YJ; Li Z; Jeeva S; Lee S; Moore ML; Kang SM Vaccine; 2019 Oct; 37(44):6656-6664. PubMed ID: 31542260 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]